The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-19 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Krypton's multiple emission lines make ionized krypton gas discharges appear whitish, which in turn makes krypton-based bulbs useful in photography as a white light source. Krypton is used in some photographic flashes for high speed photography. Krypton gas is also combined with mercury to make luminous signs that glow with a bright greenish-blue light. Krypton is mixed with argon in energy efficient fluorescent lamps, reducing the power consumption, but also reducing the light output and raising the cost. Krypton costs about 100 times as much as argon. Krypton (along with xenon) is also used to fill incandescent lamps to reduce filament evaporation and allow higher operating temperatures. Krypton's white discharge is sometimes used as an artistic effect in gas discharge "neon" tubes. Krypton produces much higher light power than neon in the red spectral line region, and for this reason, red lasers for high-power laser light-shows are often krypton lasers with mirrors that select the red spectral line for laser amplification and emission, rather than the more familiar helium-neon variety, which could not achieve the same multi-watt outputs. The krypton fluoride laser is important in nuclear fusion energy research in confinement experiments. The laser has high beam uniformity, short wavelength, and the spot size can be varied to track an imploding pellet. In experimental particle physics, liquid krypton is used to construct quasi-homogeneous electromagnetic calorimeters.
There are many types of freeze-dryers available, however, they usually contain a few essential components. These are a vacuum chamber, shelves, process condenser, shelf-fluid system, refrigeration system, vacuum system, and control system.
==== Monoaminergic activity enhancer ==== Phenethylamine is a monoaminergic activity enhancer (MAE) of serotonin, norepinephrine, and dopamine in addition to its catecholamine-releasing activity. That is, it enhances the action potential-mediated release of these monoamine neurotransmitters. The compound is active as a MAE at much lower concentrations than the concentrations at which it induces the release of catecholamines. The MAE actions of phenethylamine and other MAEs may be mediated by TAAR1 agonism. Synthetic and more potent MAEs like phenylpropylaminopentane (PPAP) and selegiline (L-deprenyl) have been derived from phenethylamine.
Reflecting its low first ionization energy of 418.8 kJ/mol, potassium is a strong reducing agent, i.e., it readily releases an electron upon contact with other materials. With graphite, potassium metal forms graphite intercalation compounds. One such compound has the formula KC8, a gold colored solid that is described as a K+ salt of negatively charged graphite. Potassium can reduce many salts to the metal as illustrated by the Rieke method for making magnesium powder from magnesium chloride:
The SpyTag/SpyCatcher system is a technology for irreversible conjugation of recombinant proteins. The peptide SpyTag (13 amino acids) spontaneously reacts with the protein SpyCatcher (12.3 kDa) to form an intermolecular isopeptide bond between the pair. DNA sequence encoding either SpyTag or SpyCatcher can be recombinantly introduced into the DNA sequence encoding a protein of interest, forming a fusion protein. These fusion proteins can be covalently linked when mixed in a reaction through the SpyTag/SpyCatcher system. Using the Tag/Catcher pair, bioconjugation can be achieved between two recombinant proteins that would otherwise be difficult or impossible with traditional direct genetic fusion between the two proteins. For example, issues regarding protein folding, suboptimal expression host, and specialized post-translational modifications may be alleviated by separating the production of the proteins with the modularity of the Tag/Catcher system.
Sources: en.wikipedia.org
Furthermore, given that deficits resulting from mTOR overactivity can be alleviated through treatment with rapamycin, it is possible that mTOR plays an important role in affecting cognitive functioning through synaptic plasticity. Further evidence for mTOR activity in neurodegeneration comes from recent findings demonstrating that eIF2α-P, an upstream target of the mTOR pathway, mediates cell death in prion diseases through sustained translational inhibition. Some evidence points to mTOR's role in reduced Aβ clearance as well. mTOR is a negative regulator of autophagy; therefore, hyperactivity in mTOR signaling should reduce Aβ clearance in the AD brain. Disruptions in autophagy may be a potential source of pathogenesis in protein misfolding diseases, including AD. Studies using mouse models of Huntington's disease demonstrate that treatment with rapamycin facilitates the clearance of huntingtin aggregates. Perhaps the same treatment may be useful in clearing Aβ deposits as well.
=== Combination therapy === Combinations of finasteride, minoxidil and ketoconazole are more effective than individual use. Combination therapy of LLLT or microneedling with finasteride or minoxidil demonstrated substantive increases in hair count.
The scalp is the area of the head where head hair grows. It is made up of skin, layers of connective and fibrous tissues, and the membrane of the skull. Anatomically, the scalp is part of the epicranium, a collection of structures covering the cranium. The scalp is bordered by the face at the front, and by the neck at the sides and back. The scientific study of hair and scalp is called trichology.
== Genetics == Biallelic pathogenic variants in GAMT are associated with guanidinoacetate methyltransferase deficiency. Over 70 variants have been reported in the GAMT gene. This gene codes for the enzyme guanidinoacetate methyltransferase (GAMT), which participates in the two-step synthesis of the compound creatine from amino acids glycine, arginine and methionine. Specifically, GAMT controls the second step of the sequence, in which creatine is produced from another compound called guanidinoacetate. GAA is toxic, and because GAMT patients lack the enzyme used to convert GAA to creatine, a build-up of GAA occurs in the brain and other tissues. This accumulation of GAA is thought to cause the more severe symptoms of GATM deficiency. The effects of GAMT deficiency are most severe in organs and tissues that require large amounts of energy, such as the brain and muscles. This disorder is inherited in an autosomal recessive manner, which means the causative gene is located on an autosome, and two defective copies of the gene – one from each parent – are required to inherit the disorder. The parents both carry one pathogenic variant; however, they are not affected by the disorder. As carriers, the residual activity of approximately 50% is enough to avoid clinical complications. Any siblings of an GAMT deficient individual have a 25% chance of also being GAMT deficient, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
Sources: en.wikipedia.org
Males expel urine from the bladder through the urethra, which passes through the prostate where it is joined by the ejaculatory ducts, and then onward through the penis. At the root of the penis (the proximal end of the corpus spongiosum) lies the external sphincter muscle, which relaxes during urination. This is a small sphincter of striated muscle tissue and is in healthy males, under voluntary control. Physiologically, urination involves coordination between the central, autonomic, and somatic nervous systems. In infants, some elderly individuals, and those with neurological injury, urination may occur as an involuntary reflex. Brain centers that regulate urination include the pontine micturition center, periaqueductal gray, and the cerebral cortex. During erection, these centers block the relaxation of the sphincter muscles, so as to act as a physiological separation of the excretory and reproductive function of the penis, and preventing urine from entering the upper portion of the urethra during ejaculation.
A Daily Telegraph report alleging a conflict-of-interest involving First Minister of Scotland Humza Yousaf after the Scottish Government donated £250,000 to the UN agency UNRWA, which supports Palestinian refugees, is rejected by Yousaf as an "outrageous smear" and a "far right conspiracy". 10 March – BBC News reports that former prime minister Boris Johnson flew to Venezuela during February for an unofficial private meeting with President Nicolás Maduro. 11 March – Ashfield MP Lee Anderson defects from the Conservatives to Reform UK, becoming the party's first sitting Member of Parliament. Addressing the Institute for Government, former prime minister Sir John Major criticises his recent Conservative successors for the attitude towards the civil service, and describes the quick succession of prime ministers in recent years as "not conducive to good government". As the UK government prepares to redraw the definition of extremism, former Home Secretaries Priti Patel, Sajid Javid and Amber Rudd warn against attempting to politicise extremism at the next election. After the Welsh Government publishes plans to require parties in the Senedd to draw up lists of candidates composing of 50% of women, presiding officer Elin Jones says that the Senedd does not have the power to enforce gender quotas. Conservative Party donor Frank Hester apologises after The Guardian reported comments he is alleged to have made in 2019 about Labour MP Diane Abbott, when he is said to have suggested she made him "want to hate all black women" and that she "should be shot".
A fuel rod is reprocessed after three years of use to remove waste products, which by then account for 3% of the total weight of the rods. Any uranium or plutonium isotopes produced during those three years are left and the rod goes back into production. The presence of up to 1% gallium per mass in weapons-grade plutonium alloy has the potential to interfere with long-term operation of a light water reactor. Plutonium recovered from spent reactor fuel poses little proliferation hazard, because of excessive contamination with non-fissile plutonium-240 and plutonium-242. Separation of the isotopes is not feasible. A dedicated reactor operating on very low burnup (hence minimal exposure of newly formed plutonium-239 to additional neutrons which causes it to be transformed to heavier isotopes of plutonium) is generally required to produce material suitable for use in efficient nuclear weapons. While "weapons-grade" plutonium is defined to contain at least 92% plutonium-239 (of the total plutonium), the United States have managed to detonate an under-20Kt device using plutonium believed to contain only about 85% plutonium-239, so called '"fuel-grade" plutonium. The "reactor-grade" plutonium produced by a regular LWR burnup cycle typically contains less than 60% Pu-239, with up to 30% parasitic Pu-240/Pu-242, and 10–15% fissile Pu-241. It is unknown if a device using plutonium obtained from reprocessed civil nuclear waste can be detonated, however such a device could hypothetically fizzle and spread radioactive materials over a large urban area.
Direct adrenergic agents such as epinephrine, norepinephrine, phenylephrine, isoproterenol, and dobutamine may be used when clinically necessary, but reduced initial doses and careful monitoring are advised because of possible potentiation. Phenelzine has also been linked to reduced vitamin B6 levels and pyridoxine deficiency. Modern guidance considers pyridoxine hydrochloride supplementation advisable with phenelzine, either from the start of treatment or if related adverse effects appear, according to clinician preference, and specifically recommends it when paresthesia or peripheral neuropathy occurs. Transaminases such as GABA-transaminase have been shown to be dependent upon vitamin B6 and may be involved in a potentially related process, since the phenelzine metabolite phenylethylidenehydrazine (PEH) is a GABA-transaminase inhibitor. Both phenelzine and vitamin B6 are rendered inactive upon these reactions occurring. The pyridoxine form of B6 is generally preferred for supplementation in this context, since this form has been shown to reduce hydrazine toxicity from phenelzine and, in contrast, the pyridoxal form has been shown to increase the toxicity of hydrazines.
Tony Cliff (born Yigael Glückstein, Hebrew: יגאל גליקשטיין; 20 May 1917 – 9 April 2000); Trotskyist anti-Zionist; prolific author of over twenty books, scholarly monographs and papers, pamphleteer and radical leftist activist, born in Ottoman Palestine; moved to Britain in 1947; assumed pen name 'Tony Cliff'; founding member and leader of Socialist Review Group, which became the International Socialists and then the Socialist Workers Party. Chapman Cohen writer on secularism Jackie Collins OBE (4 October 1937 – 19 September 2015) was an English romance novelist and actress. She wrote 32 novels, all of which appeared on The New York Times Best Seller list. Alan Coren (27 June 1938 – 18 October 2007) was an English humourist, writer and satirist who was a regular panellist on the BBC radio quiz The News Quiz and a team captain on BBC television's Call My Bluff. Coren, the author of over twenty books, was also a journalist, and for almost a decade was the editor of Punch magazine. His children, Giles and Victoria, are also writers Edwina Currie (née Cohen; born 13 October 1946) writer of six novels, broadcaster and former politician and media personality; from 1998 to 2003, hosted late evening talk show on BBC Radio 5 Live, Late Night Currie; moved to HTV, presenting Currie Night; has appeared in string of reality television programmes.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.